During the EF-14 phase III pivotal trial, 695 patients of both sexes with a newly-diagnosed glioblastoma were investigated. They had first undergone surgery, then combined chemoradiotherapy that included the administration of temozolomide (TMZ). Subsequently, the patients were treated either with temozolomide maintenance therapy alone or with the addition of Optune (Optune + TMZ).
The results of the EF-14 study show that combining Optune and TMZ is significantly more beneficial than TMZ therapy alone. Combined therapy with Optune + TMZ significantly prolongs the median overall survival compared to therapy with TMZ only.
